Table 4. Enzyme-linked immunospot (ELISPOT) responses against antigenic peptides in the absence or presence of HLA class I or HLA class II blocking antibodies.

					SFC/1×105 PBMC+Peptide
Peptide	Name	Sequence	HLA-I	KD (nM)	Donor#	Isotype	W6/32	IVA12
PF-96 a	NP140–148	HSNLNDTTY	A1	130	32	10±1	6±1* c	14±1
PF-103	NS1128–136	IMLKANFSV	A2	1	1	24±2	23±5	1±1 *
PF-116	NA148–156	TIHDRIPHR	A3	62	29	120±21	121±10	9±2 *
PF-106	M1109–117	FYGAKEIAL	A24	42	21	104±4	65±6 *	14±3 *
PF-109	HA407–415	KFHQIEKEF	A24	1	25	60±24	73±8	1±2 *
PF-110	HA315–323	VTIGECPKY	A26	20000	25	163±28	165±4	5±3 *
PF-113	NS1142–150	ETIVLLRAF	A26	28	25	96±6	105±16	2±1*
PF-145 a	NA281–289	YPRYPGVRC	B7	11	21	29±4	10±5*	39±7
PF-146	M224–32	DPLVVAASI	B7	20000	31	17±1	18±3	2±2*
PF-147	HA303–311	LPFHNVHPL	B7	6	23	62±3	61±16	2±2 *
PF-148	HA544–552	LVSLGAISF	B7	20000	23	147±11	187±23	75±49 *
PF-150	HA307–315	LPFQNVHPV	B7	161	31	150±7	130±13	3±2 *
PF-152	HA324–332	YVKQNTLKL	B7	72	32	10±3	5±2	0±1 *
PF-154	HA266–274	IAPWYAFAL	B8	7559	23	38±15	38±10	1±1 *
PF-156	M1208–216	QARRMVQAM	B8	87	14	59±4	67±16	2±2 *
PF-130 a,b	NP251–259	AEIEDLIFL	B44	1	9	73±3	40±4 *	81±2
PF-132 a	M17–15	VETYVLSII	B44	13	2	34±8	2±1 *	43±13
PF-135 a	NS1179–187	GVLIGGLEW	B58	553	36	30±7	4±4 *	26±10
PF-137	NS26–14	VSSFQDILL	B58	687	35	18±4	16±1	19±4
PF-140	M239–47	ILWILDRLF	B62	20000	29	32±3	43±19	1±1*
PF-141	NA159–167	LMNELGVPF	B62	194	17	152±21	66±21*	2±2 *

^aReactivity inhibited by anti-HLA class I mAb represents HLA-I restricted epitopes.

^bIndicates already known epitope.

^c*significant inhibition, P<0.05.